Next-Generation Sequencing (NGS) | Explore the technology
Next-generation sequencing (NGS) is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA.
Next-generation sequencing for beginners - Illumina
These next-generation sequencing (NGS) tutorials are designed to help you understand key concepts in NGS. With videos, online training, and knowledge articles, we’ll guide you through tips and best practices for library prep, sequencing, and data analysis.
TruSight Oncology 500 | Enable CGP utilizing DNA and RNA
TruSight Oncology 500 (TSO 500) is an NGS assay that enables in-house comprehensive genomic profiling (CGP) from FFPE tissue. Targets 523 genes to assess all DNA and RNA variant types (SNV, CNV, indels, fusions), plus MSI, TMB and …
NGS Workflow Steps | Illumina sequencing workflow
The next-generation sequencing workflow contains three basic steps: library preparation, sequencing, and data analysis.
DesignStudio Assay Design Tool | Software for custom array
DesignStudio is a web-based assay design tool to help researchers design and order custom genotyping microarray probes or custom sequencing assays.
NGS vs qPCR - Illumina
When comparing next-generation sequencing (NGS) vs quantitative PCR (qPCR) technologies, the key difference is discovery power. While both offer highly sensitive and reliable variant detection, qPCR can only detect known sequences.
IVD Assay Development | Develop IVD assays using FDA ... - Illumina
Develop your own IVD assays on the MiSeqDx System, the first FDA-regulated and CE-IVD-marked next-generation sequencing system for in vitro diagnostic use.
TruSight Cystic Fibrosis | Detect cystic fibrosis variants with NGS
TruSight Cystic Fibrosis is an FDA-regulated, CE-marked IVD NGS assay that provides two cystic fibrosis tests for carrier screening, confirmatory diagnostic testing of newborns and children, initial testing to aid in diagnosis (TruSight Cystic Fibrosis 139-Variant Assay), and testing in atypical presentations or when other panels have failed to ...
TruSight Oncology 500 ctDNA v2 | Enable CGP from ctDNA in
TruSight Oncology 500 ctDNA v2 is a pan-cancer NGS assay that enables in-house comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in blood plasma for research. Leverage low cfDNA inputs (20 ng) from minimally invasive blood samples to achieve sensitive and accurate detection (0.2% VAF for SNVs) using UMI-based hybrid-capture ...
Illumina Protein Prep | Detect and quantify proteins with NGS
Illumina Protein Prep enables discovery and quantification of human proteins across more than 200 biological pathways using a SOMAmer-based proteomics assay with an NGS readout.